GSK_Annual_Report_2021

Notes to the Standalone Financial Statements for the year ended March 31, 2021 (contd.) Annual Report 2020-21 147 Note 52 : Share-based payment arrangements Restricted Share Awards (RSAs) Certain employees of the Company are entitled to receive cash settled stock based awards (‘awards’) pursuant to employee share schemes (‘scheme’) administered by GlaxoSmithKline Plc. (‘Plc’). Under this plan, certain employees are granted cash settled RSAs at no cost, which entitle them to receive cash equivalent to the stock price of the Plc’s shares listed at London stock exchange after two and a half to three year vesting period during which the employee has to remain in continuous employment with the Company. These RSA’s do not give any voting rights or the right to accrue dividends. The fair value of these awards is determined based on the closing share price on the day of grant, after deducting the expected future dividend yield of 5% (Previous Year 4.2%) over the duration of the award. Reconciliation of RSAs Number of RSA As at April 1, 2019 139,839 Granted 122,201 Exercised * (43,148) Cancelled** (50,616) As at March 31, 2020 168,276 Granted 95,703 Exercised * (61,387) Cancelled** (37,408) As at March 31, 2021 165,184 *The weighted average share price at the date of exercise of the awards exercised during the year ended March 31, 2021 was GBP 12.88 (March 31, 2020 GBP 15.15) ** Also includes for employees transferred Expense arising from share-based payment transactions Total expenses arising from share-based payment transactions recognised in the Statement of Profit and Loss as part of employee benefit expense were as follows: ( ` in lakhs) Year ended March 31, 2021 Year ended March 31, 2020 Restricted Share Awards (RSAs) 12,85.06 13,21.17 Carrying amount of liability ( ` in lakhs) As at March 31, 2021 As at March 31, 2020 Carrying amount of liability included in long term incentive plan (Notes 21 and 25) 13,04.42 10,06.07 Note 53 : Event occurring after balance sheet date The Board of Directors has recommended a Dividend of ` 30 per equity share of face value of ` 10 each for this year. (March 31, 2020: ` 40 per share) (Refer Note 49 (b)).